Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878657 · ClinicalTrials.gov registry record · Phase 1
Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00878657 is a Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 8 participants.
The verdict
NCT00878657, a Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving intensity-modulated radiation therapy together with gemcitabine may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of intensity-modulated radiation therapy and to see how well it works when given together with gemcitabine in treating patients with locally advanced pancreatic cancer.
Interventions
- RADIATION intensity-modulated radiation therapy
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878657
The ClinicalTrials.gov registry entry for NCT00878657 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT00878657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878657 about?
NCT00878657 is a clinical study titled "Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer". RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cel...
What is the current status of trial NCT00878657?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-04. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00878657?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00878657?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.